Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
6MW3211 in Advanced Malignant Neoplasm
NCT05048160Phase 2Unknown
- Sponsor
- Mabwell
- Start
- Sep 2021
- Primary completion
- Jun 2024
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of 6MW3211 in cancer, sponsored by Mabwell. Status: unknown.
02
Drugs
6MW3211
03
Conditions
cancer
Beyond the preview
Go deeper on NCT05048160.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05048160.